{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:59:33Z","timestamp":1781665173091,"version":"3.54.5"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001116","name":"Foundation Fighting Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018576","name":"University Hospitals Harrington Discovery Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018576","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jconrel.2025.113659","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T18:51:12Z","timestamp":1742842272000},"page":"113659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Delivery of a novel neuroprotective compound to the retina in rat and rabbit animal models"],"prefix":"10.1016","volume":"382","author":[{"given":"Meredith","family":"Garrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri","family":"Feris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abe","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen F.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Kastellorizios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.113659_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122625","article-title":"Reverse engineering the Ozurdex dexamethasone intravitreal implant","volume":"634","author":"Costello","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113659_bb0010","article-title":"Intravitreal devices for the treatment of vitreous inflammation","volume":"2012","author":"Christoforidis","year":"2012","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.jconrel.2025.113659_bb0015","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2214-109X(20)30425-3","article-title":"Vision loss expert Group of the Global Burden of disease, trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the global burden of disease study","volume":"9","author":"Blindness","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jconrel.2025.113659_bb0020","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/bjophthalmol-2011-300539","article-title":"Global estimates of visual impairment: 2010","volume":"96","author":"Pascolini","year":"2012","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113659_bb0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejpb.2015.01.003","article-title":"Intravitreal clearance and volume of distribution of compounds in rabbits: in silico prediction and pharmacokinetic simulations for drug development","volume":"95","author":"del Amo","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2025.113659_bb0030","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1111\/bph.14024","article-title":"Principles of pharmacology in the eye","volume":"174","author":"Awwad","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.113659_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010134","article-title":"Topical drug delivery to the posterior segment of the eye","volume":"14","author":"Loscher","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113659_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041094","article-title":"Overcoming treatment challenges in posterior segment diseases with biodegradable Nano-based drug delivery systems","volume":"15","author":"Wu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113659_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115005","article-title":"A new era in posterior segment ocular drug delivery: translation of systemic, cell-targeted, dendrimer-based therapies","volume":"200","author":"Kannan","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113659_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071862","article-title":"Innovative strategies for drug delivery to the ocular posterior segment","volume":"15","author":"Gabai","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113659_bb0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/ICU.0000000000000850","article-title":"Complications of intravitreal injections: 2022","volume":"33","author":"Patel","year":"2022","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113659_bb0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nyas.14662","article-title":"A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways","volume":"1502","author":"Klein","year":"2021","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.jconrel.2025.113659_bb0065","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s11095-021-03149-y","article-title":"Research and education needs for complex generics","volume":"38","author":"Stern","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.113659_bb0070","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/jps.21987","article-title":"A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases","volume":"99","author":"Choonara","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113659_bb0075","article-title":"Considerations for polymers used in ocular drug delivery","volume":"8","author":"Allyn","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.jconrel.2025.113659_bb0080","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1021\/acs.molpharmaceut.2c00945","article-title":"Influence of PLGA end groups on the release profile of dexamethasone from ocular implants","volume":"20","author":"Saraf","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.113659_bb0085","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.2147\/OPTH.S427976","article-title":"Phase 3, randomized study comparing Intracameral Bimatoprost implant 15 microg and selective laser trabeculectomy in patients with open-angle Glaucoma or ocular hypertension","volume":"17","author":"Christie","year":"2023","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113659_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122728","article-title":"PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases","volume":"14","author":"Alsaab","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113659_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030614","article-title":"Challenges and complications of poly(lactic-co-glycolic acid)-based long-acting drug product development","volume":"14","author":"Lim","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113659_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16111467","article-title":"Formulation, characterisation, and biocompatibility assessment of rifampicin-loaded Poly(d,l-lactide-co-glycolide) composites for local treatment of orthopaedic and wound infections","volume":"16","author":"Singhal","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113659_bb0105","article-title":"Investigation of degradation and biocompatibility of indirect 3D-printed bile duct stents","volume":"11","author":"Lee","year":"2024","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/j.jconrel.2025.113659_bb0110","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s13346-020-00769-6","article-title":"From micro to nano: evolution and impact of drug delivery in treating disease","volume":"10","author":"Hrkach","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2025.113659_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23042034","article-title":"PLGA-based composites for various biomedical applications","volume":"23","author":"Rocha","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.113659_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030454","article-title":"Properties of poly (lactic-co-glycolic acid) and progress of poly (lactic-co-glycolic acid)-based biodegradable materials in biomedical research","volume":"16","author":"Lu","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jconrel.2025.113659_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061188","article-title":"Effects of drug physicochemical properties on in-situ forming implant polymer degradation and drug release kinetics","volume":"14","author":"Joiner","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113659_bb0130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijpharm.2015.03.026","article-title":"In-situ forming composite implants for periodontitis treatment: how the formulation determines system performance","volume":"486","author":"Do","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113659_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119339","article-title":"The effect of PLGA molecular weight differences on risperidone release from microspheres","volume":"582","author":"Kohno","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113659_bb0140","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/17425247.5.9.1039","article-title":"Iluvien: a new sustained delivery technology for posterior eye disease","volume":"5","author":"Kane","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.113659_bb0145","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fbioe.2020.00048","article-title":"The design of Poly(lactide-co-glycolide) nanocarriers for medical applications","volume":"8","author":"Essa","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.113659_bb0150","first-page":"665","article-title":"Long-acting Fluocinolone Acetonide intravitreal implant for recurrent bilateral non-infectious posterior uveitis","volume":"15","author":"Babel","year":"2022","journal-title":"Int. Med. Case Rep. J."},{"key":"10.1016\/j.jconrel.2025.113659_bb0155","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.2174\/1389450121666200428101738","article-title":"New anti-VEGF drugs in ophthalmology","volume":"21","author":"Campa","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.jconrel.2025.113659_bb0160","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s13346-021-01043-z","article-title":"In vitro dissolution testing models of ocular implants for posterior segment drug delivery","volume":"12","author":"Adrianto","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2025.113659_bb0165","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/jps.24480","article-title":"The PK-eye: a novel in vitro ocular flow model for use in preclinical drug development","volume":"104","author":"Awwad","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113659_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15102472","article-title":"Development of ARPE-19-equipped ocular cell model for in vitro investigation on ophthalmic formulations","volume":"15","author":"Sapino","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113659_bb0175","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jconrel.2021.03.024","article-title":"Adaptive perfusion: an in vitro release test (IVRT) for complex drug products","volume":"333","author":"Patel","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113659_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119761","article-title":"In vitro physicochemical characterization and dissolution of brinzolamide ophthalmic suspensions with similar composition","volume":"588","author":"Vo","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113659_bb0185","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv Transl. Res."},{"key":"10.1016\/j.jconrel.2025.113659_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2021035222","article-title":"Role of in vitro models for development of ophthalmic delivery systems","volume":"38","author":"Kutlehria","year":"2021","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2025.113659_bb0195","doi-asserted-by":"crossref","first-page":"16129","DOI":"10.1038\/s41598-024-67069-8","article-title":"Establishment of an in vitro choroid complex system for vascular response screening","volume":"14","author":"Jeong","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.113659_bb0200","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s42826-022-00128-1","article-title":"Role of animal models in biomedical research: a review","volume":"38","author":"Mukherjee","year":"2022","journal-title":"Lab. Anim. Res."},{"key":"10.1016\/j.jconrel.2025.113659_bb0205","article-title":"The importance of animal models in biomedical research: current insights and applications","volume":"13","author":"Dominguez-Oliva","year":"2023","journal-title":"Animals (Basel)"},{"key":"10.1016\/j.jconrel.2025.113659_bb0210","series-title":"Boorman\u2019s Pathology of the Rat","article-title":"Eye and associated glands","author":"Dale","year":"2018"},{"key":"10.1016\/j.jconrel.2025.113659_bb0215","series-title":"Special Senses: Eye, in: Comparative Anatomy and Histology","first-page":"445","author":"Caroline","year":"2018"},{"key":"10.1016\/j.jconrel.2025.113659_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123973","article-title":"In-situ forming biodegradable implants for sustained Fluocinolone acetonide release to the posterior eye: in-vitro and in-vivo investigations in rabbits","volume":"654","author":"Karimi","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113659_bb0225","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1871527315666151110124957","article-title":"Senin, II, rabbit models of ocular diseases: new relevance for classical approaches","volume":"15","author":"Zernii","year":"2016","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.jconrel.2025.113659_bb0230","article-title":"Preparation and evaluation of Nanofibrous and film-structured ciprofloxacin hydrochloride inserts for sustained ocular delivery: pharmacokinetic study in Rabbit\u2019s eye","volume":"13","author":"Taghe","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jconrel.2025.113659_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105720","article-title":"Pharmacokinetics of intravitreal macromolecules: scaling between rats and rabbits","volume":"159","author":"Sadeghi","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113659_bb0240","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.exer.2015.05.003","article-title":"Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data","volume":"137","author":"Del Amo","year":"2015","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2025.113659_bb0245","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.drudis.2019.05.035","article-title":"Challenges and opportunities for drug delivery to the posterior of the eye","volume":"24","author":"Cabrera","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2025.113659_bb0250","doi-asserted-by":"crossref","first-page":"20753","DOI":"10.1038\/s41598-022-24537-3","article-title":"sigma(2)R\/TMEM97 in retinal ganglion cell degeneration","volume":"12","author":"Wang","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.113659_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120105","article-title":"Effect of implant formation on drug release kinetics of in situ forming implants","volume":"592","author":"Suh","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113659_bb0260","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1021\/acschemneuro.8b00543","article-title":"Neuroprotective efficacy of a sigma 2 receptor\/TMEM97 modulator (DKR-1677) after traumatic brain injury","volume":"10","author":"Vazquez-Rosa","year":"2019","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.jconrel.2025.113659_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115488","article-title":"Structure-affinity relationships of stereoisomers of norbenzomorphan-derived sigma(2)R\/TMEM97 modulators","volume":"257","author":"Lu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.113659_bb0270","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1021\/acsmedchemlett.7b00066","article-title":"Norbenzomorphan scaffold: chemical tool for modulating sigma receptor-subtype selectivity","volume":"8","author":"Sahn","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2025.113659_bb0275","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1167\/iovs.65.8.16","article-title":"H-151, a selective STING inhibitor, has potential as a treatment for neovascular age-related macular degeneration","volume":"65","author":"Tanaka","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2025.113659_bb0280","doi-asserted-by":"crossref","first-page":"132","DOI":"10.21873\/invivo.13811","article-title":"Therapeutic potential of dimethyl sulfoxide via subconjunctival injection in a diabetic retinopathy rat model","volume":"39","author":"Hwang","year":"2025","journal-title":"In Vivo"},{"key":"10.1016\/j.jconrel.2025.113659_bb0285","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10633-009-9191-8","article-title":"Dimethyl sulphoxide dose-response on rat retinal function","volume":"119","author":"Tsai","year":"2009","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113659_bb0290","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF00150975","article-title":"Ocular toxicity of experimental intravitreal itraconazole","volume":"15","author":"Schulman","year":"1991","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113659_bb0295","first-page":"193","article-title":"Ocular toxicity of experimental intravitreal DMSO","volume":"2","author":"Silverman","year":"1983","journal-title":"J. Toxicol.: Cutan. Ocul. Toxicol."},{"key":"10.1016\/j.jconrel.2025.113659_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2022.111102","article-title":"Robust strategies to reduce burst and achieve tunable control over extended drug release from uniaxially electrospun composites","volume":"168","author":"Joy","year":"2022","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.jconrel.2025.113659_bb0305","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/10837450.2021.1944207","article-title":"An overview of PLGA in-situ forming implants based on solvent exchange technique: effect of formulation components and characterization","volume":"26","author":"Ibrahim","year":"2021","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jconrel.2025.113659_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113912","article-title":"Drug release from in situ forming implants and advances in release testing","volume":"178","author":"Wang","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113659_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121777","article-title":"Novel adapter method for in vitro release testing of in situ forming implants","volume":"621","author":"Wang","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113659_bb0320","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jconrel.2024.09.045","article-title":"Implant dynamics, inner structure, and their impact on drug release of in situ forming implants uncovered through CT imaging","volume":"375","author":"Lin","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113659_bb0325","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jconrel.2013.08.024","article-title":"PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release","volume":"172","author":"Parent","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113659_bb0330","article-title":"PLGA implants for controlled dexamethasone delivery: impact of the polymer chemistry","volume":"86","author":"Wachowiak","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2025.113659_bb0335","article-title":"Optimization of injectable PLGA in-situ forming implants of anti-psychotic risperidone via box-Behnken design","volume":"58","author":"Ibrahim","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2025.113659_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16010115","article-title":"Burst release from in situ forming PLGA-based implants: 12 effectors and ways of correction","volume":"16","author":"Bakhrushina","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113659_bb0345","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23071719","article-title":"Salts of therapeutic agents: chemical, physicochemical, and biological considerations","volume":"23","author":"Gupta","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2025.113659_bb0350","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jconrel.2022.09.056","article-title":"Combining drug salt formation with amorphous solid dispersions - a double edged sword","volume":"352","author":"Hiew","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113659_bb0355","article-title":"Exploring the solubility and bioavailability of sodium salt and its free acid solid dispersions of Dolutegravir","volume":"2023","author":"Yarlagadda","year":"2023","journal-title":"Adv. Pharmacol. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113659_bb0360","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejpb.2022.04.002","article-title":"Combining enabling formulation strategies to generate supersaturated solutions of delamanid: in situ salt formation during amorphous solid dispersion fabrication for more robust release profiles","volume":"174","author":"Duong","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2025.113659_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26113113","article-title":"Enantioselectivity in drug pharmacokinetics and toxicity: pharmacological relevance and analytical methods","volume":"26","author":"Coelho","year":"2021","journal-title":"Molecules"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925002792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925002792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:05:33Z","timestamp":1777871133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925002792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":73,"alternative-id":["S0168365925002792"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113659","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivery of a novel neuroprotective compound to the retina in rat and rabbit animal models","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113659"}}